Brief: Vir Biotechnology Q2 EPS USD -0.8

Vir Biotechnology

06/08/2025 21:05

Overview

Vir Q2 revenue of $1.2 mln missed analyst expectations, per LSEG data

Net loss for Q2 was $111 mln, or $0.80 per share, narrows yr/yr

Company maintains strong cash position with $892.1 mln, runway into mid-2027

Outlook

Vir expects cash to fund operations into mid-2027

Result Drivers

COST SAVINGS - Reduction in R&D and SG&A expenses attributed to restructuring initiatives

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Miss
$1.20 mln
$2.72 mln (6 Analysts)
Q2 EPS
-$0.8
Q2 Net Income
-$111 mln
Q2 Cash & Investments
$892.10 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Vir Biotechnology Inc is $15.50, about 67% above its August 5 closing price of $5.11

Press Release: ID:nBw5b8fyza

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)